Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Glia. 2020 Jul 8;68(10):2148–2166. doi: 10.1002/glia.23883

FIGURE 7.

FIGURE 7

Murine PDGFB-overexpressing and Nf1-silenced tumors do not respond to PD-L1 neutralizing therapy. (a) Schematic illustration of the experimental protocol. (b) Survival curves comparing mice bearing PDGFB-overexpressing tumors treated with isotype control antibody (N = 11), PD-L1 neutralizing antibody (N = 10), isotype control antibody plus x-ray irradiation (N = 8), and PD-L1 neutralizing antibody plus X-ray irradiation (N = 9). (c) Survival curves comparing mice bearing NF1-silenced tumors treated with isotype control antibody plus X-ray irradiation (N = 7) and PD-L1 neutralizing antibody plus X-ray irradiation (N = 6). Mantel-Cox (MC) and Gehan-Breslow-Wilcoxon (GBW) tests, (ns) not significant, ***p < .001, ****p < .0001. RT, X-ray radiation therapy